Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly

Sarah Westwood, Emanuela Leoni, Abdul Hye, Steven Lynham, Mizanur R. Khondoker, Nicholas J. Ashton, Steven J. Kiddle, Alison L. Baird, Ricardo Sainz-Fuertes, Rufina Leung, John Graf, Cristina Tan Hehir, David Baker, Cristina Cereda, Chantal Bazenet, Malcolm Ward, Madhav Thambisetty, Simon Lovestone

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Increasingly, clinical trials for Alzheimer's disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and the screening failure rate is likely to be high. Having a blood-based marker that would reduce such costs and accelerate clinical trials through identifying potential participants with likely pre-clinical AD would be a substantial advance. In order to seek such a candidate biomarker, discovery phase proteomic analyses using 2DGE and gel-free LC-MS/MS for high and low molecular weight analytes were conducted on longitudinal plasma samples collected over a 12-year period from non-demented older individuals who exhibited a range of 11C-PiB PET measures of amyloid load. We then sought to extend our discovery findings by investigating whether our candidate biomarkers were also associated with brain amyloid burden in disease, in an independent cohort. Seven plasma proteins, including A2M, Apo-A1, and multiple complement proteins, were identified as pre-clinical biomarkers of amyloid burden and were consistent across three time points (p <0.05). Five of these proteins also correlated with brain amyloid measures at different stages of the disease (q <0.1). Here we show that it is possible to detect a plasma based biomarker signature indicative of AD pathology at a stage long before the onset of clinical disease manifestation. As in previous studies, acute phase reactants and inflammatory markers dominate this signature.

Original languageEnglish
Pages (from-to)561-572
Number of pages12
JournalJournal of Alzheimer's Disease
Volume52
Issue number2
DOIs
Publication statusPublished - May 10 2016

Fingerprint

Amyloid
Biomarkers
Alzheimer Disease
Clinical Trials
Pathology
Acute-Phase Proteins
Apolipoprotein A-I
Brain
Proteomics
Blood Proteins
Complement System Proteins
Molecular Weight
Gels
Costs and Cost Analysis
Proteins

Keywords

  • Alzheimer's disease
  • amyloid
  • biological markers
  • blood
  • plasma
  • preclinical
  • proteomics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Westwood, S., Leoni, E., Hye, A., Lynham, S., Khondoker, M. R., Ashton, N. J., ... Lovestone, S. (2016). Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. Journal of Alzheimer's Disease, 52(2), 561-572. https://doi.org/10.3233/JAD-151155

Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. / Westwood, Sarah; Leoni, Emanuela; Hye, Abdul; Lynham, Steven; Khondoker, Mizanur R.; Ashton, Nicholas J.; Kiddle, Steven J.; Baird, Alison L.; Sainz-Fuertes, Ricardo; Leung, Rufina; Graf, John; Hehir, Cristina Tan; Baker, David; Cereda, Cristina; Bazenet, Chantal; Ward, Malcolm; Thambisetty, Madhav; Lovestone, Simon.

In: Journal of Alzheimer's Disease, Vol. 52, No. 2, 10.05.2016, p. 561-572.

Research output: Contribution to journalArticle

Westwood, S, Leoni, E, Hye, A, Lynham, S, Khondoker, MR, Ashton, NJ, Kiddle, SJ, Baird, AL, Sainz-Fuertes, R, Leung, R, Graf, J, Hehir, CT, Baker, D, Cereda, C, Bazenet, C, Ward, M, Thambisetty, M & Lovestone, S 2016, 'Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly', Journal of Alzheimer's Disease, vol. 52, no. 2, pp. 561-572. https://doi.org/10.3233/JAD-151155
Westwood, Sarah ; Leoni, Emanuela ; Hye, Abdul ; Lynham, Steven ; Khondoker, Mizanur R. ; Ashton, Nicholas J. ; Kiddle, Steven J. ; Baird, Alison L. ; Sainz-Fuertes, Ricardo ; Leung, Rufina ; Graf, John ; Hehir, Cristina Tan ; Baker, David ; Cereda, Cristina ; Bazenet, Chantal ; Ward, Malcolm ; Thambisetty, Madhav ; Lovestone, Simon. / Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. In: Journal of Alzheimer's Disease. 2016 ; Vol. 52, No. 2. pp. 561-572.
@article{e35373917f4246518088b5f223b3e264,
title = "Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly",
abstract = "Increasingly, clinical trials for Alzheimer's disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and the screening failure rate is likely to be high. Having a blood-based marker that would reduce such costs and accelerate clinical trials through identifying potential participants with likely pre-clinical AD would be a substantial advance. In order to seek such a candidate biomarker, discovery phase proteomic analyses using 2DGE and gel-free LC-MS/MS for high and low molecular weight analytes were conducted on longitudinal plasma samples collected over a 12-year period from non-demented older individuals who exhibited a range of 11C-PiB PET measures of amyloid load. We then sought to extend our discovery findings by investigating whether our candidate biomarkers were also associated with brain amyloid burden in disease, in an independent cohort. Seven plasma proteins, including A2M, Apo-A1, and multiple complement proteins, were identified as pre-clinical biomarkers of amyloid burden and were consistent across three time points (p <0.05). Five of these proteins also correlated with brain amyloid measures at different stages of the disease (q <0.1). Here we show that it is possible to detect a plasma based biomarker signature indicative of AD pathology at a stage long before the onset of clinical disease manifestation. As in previous studies, acute phase reactants and inflammatory markers dominate this signature.",
keywords = "Alzheimer's disease, amyloid, biological markers, blood, plasma, preclinical, proteomics",
author = "Sarah Westwood and Emanuela Leoni and Abdul Hye and Steven Lynham and Khondoker, {Mizanur R.} and Ashton, {Nicholas J.} and Kiddle, {Steven J.} and Baird, {Alison L.} and Ricardo Sainz-Fuertes and Rufina Leung and John Graf and Hehir, {Cristina Tan} and David Baker and Cristina Cereda and Chantal Bazenet and Malcolm Ward and Madhav Thambisetty and Simon Lovestone",
year = "2016",
month = "5",
day = "10",
doi = "10.3233/JAD-151155",
language = "English",
volume = "52",
pages = "561--572",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly

AU - Westwood, Sarah

AU - Leoni, Emanuela

AU - Hye, Abdul

AU - Lynham, Steven

AU - Khondoker, Mizanur R.

AU - Ashton, Nicholas J.

AU - Kiddle, Steven J.

AU - Baird, Alison L.

AU - Sainz-Fuertes, Ricardo

AU - Leung, Rufina

AU - Graf, John

AU - Hehir, Cristina Tan

AU - Baker, David

AU - Cereda, Cristina

AU - Bazenet, Chantal

AU - Ward, Malcolm

AU - Thambisetty, Madhav

AU - Lovestone, Simon

PY - 2016/5/10

Y1 - 2016/5/10

N2 - Increasingly, clinical trials for Alzheimer's disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and the screening failure rate is likely to be high. Having a blood-based marker that would reduce such costs and accelerate clinical trials through identifying potential participants with likely pre-clinical AD would be a substantial advance. In order to seek such a candidate biomarker, discovery phase proteomic analyses using 2DGE and gel-free LC-MS/MS for high and low molecular weight analytes were conducted on longitudinal plasma samples collected over a 12-year period from non-demented older individuals who exhibited a range of 11C-PiB PET measures of amyloid load. We then sought to extend our discovery findings by investigating whether our candidate biomarkers were also associated with brain amyloid burden in disease, in an independent cohort. Seven plasma proteins, including A2M, Apo-A1, and multiple complement proteins, were identified as pre-clinical biomarkers of amyloid burden and were consistent across three time points (p <0.05). Five of these proteins also correlated with brain amyloid measures at different stages of the disease (q <0.1). Here we show that it is possible to detect a plasma based biomarker signature indicative of AD pathology at a stage long before the onset of clinical disease manifestation. As in previous studies, acute phase reactants and inflammatory markers dominate this signature.

AB - Increasingly, clinical trials for Alzheimer's disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology. However, making such a pre-clinical AD diagnosis is relatively costly and the screening failure rate is likely to be high. Having a blood-based marker that would reduce such costs and accelerate clinical trials through identifying potential participants with likely pre-clinical AD would be a substantial advance. In order to seek such a candidate biomarker, discovery phase proteomic analyses using 2DGE and gel-free LC-MS/MS for high and low molecular weight analytes were conducted on longitudinal plasma samples collected over a 12-year period from non-demented older individuals who exhibited a range of 11C-PiB PET measures of amyloid load. We then sought to extend our discovery findings by investigating whether our candidate biomarkers were also associated with brain amyloid burden in disease, in an independent cohort. Seven plasma proteins, including A2M, Apo-A1, and multiple complement proteins, were identified as pre-clinical biomarkers of amyloid burden and were consistent across three time points (p <0.05). Five of these proteins also correlated with brain amyloid measures at different stages of the disease (q <0.1). Here we show that it is possible to detect a plasma based biomarker signature indicative of AD pathology at a stage long before the onset of clinical disease manifestation. As in previous studies, acute phase reactants and inflammatory markers dominate this signature.

KW - Alzheimer's disease

KW - amyloid

KW - biological markers

KW - blood

KW - plasma

KW - preclinical

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=84971350904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971350904&partnerID=8YFLogxK

U2 - 10.3233/JAD-151155

DO - 10.3233/JAD-151155

M3 - Article

VL - 52

SP - 561

EP - 572

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -